Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man.

× No keyword cloud information.

40 in total

Review 1. Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors: L A Pagliaro; L Z Benet
Journal: J Pharmacokinet Biopharm Date: 1975-10

Review 2. Drug dosage in the elderly: dermatological drugs.

Authors: Anna Flammiger; Howard Maibach
Journal: Drugs Aging Date: 2006 Impact factor: 3.923

Review 3. Mass balance studies, with a focus on anticancer drugs.

Authors: Jan H Beumer; Jos H Beijnen; Jan H M Schellens
Journal: Clin Pharmacokinet Date: 2006 Impact factor: 6.447

Review 4. Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?

Authors: P Ranganathan; S Eisen; W M Yokoyama; H L McLeod
Journal: Ann Rheum Dis Date: 2003-01 Impact factor: 19.103

Review 5. Antineoplastic drugs in 1990. A review (Part II).

Authors: D J Black; R B Livingston
Journal: Drugs Date: 1990-05 Impact factor: 9.546

Review 6. Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases.

Authors: Jirí Grim; Jaroslav Chládek; Jirina Martínková
Journal: Clin Pharmacokinet Date: 2003 Impact factor: 6.447

7. The pharmacokinetics of 7-hydroxymethotrexate following medium-dose methotrexate therapy.

Authors: A L Stewart; J M Margison; P M Wilkinson; S B Lucas
Journal: Cancer Chemother Pharmacol Date: 1985 Impact factor: 3.333

8. Methyldopa kinetics before and after ingestion of methyldopa for eight weeks.

Authors: N R Campbell; A Skerjanec; Y Tam; S Robertson; E Burgess
Journal: Eur J Clin Pharmacol Date: 1995 Impact factor: 2.953

Review 9. Pharmacokinetics of anticancer drugs in children.

Authors: W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal: Clin Pharmacokinet Date: 1987-03 Impact factor: 6.447

10. Serum profiles and safety of intermediate-dose (500-1,000 mg) methotrexate following IV and IM administration.

Authors: B M Colls; R A Robson; B A Robinson; G W Tisch
Journal: Cancer Chemother Pharmacol Date: 1983 Impact factor: 3.333